Pfizer Wins Canadian Order Blocking Generic Version of Lipitor

From Bloomberg:
Pfizer Inc., the world's biggest drugmaker, won a Canadian appeals court ruling blocking regulatory approval of Ranbaxy Laboratories Ltd.'s generic version of the cholesterol pill Lipitor.

Canada's Federal Court of Appeal yesterday reversed a lower-court ruling that Ranbaxy could seek approval for its competing version of Lipitor before Pfizer's patent expires in 2010, Pfizer spokeswoman Vanessa Aristide said in a phone interview.

Ranbaxy, India's largest drugmaker, also challenged Lipitor patents in the Netherlands. Pfizer said in February it would appeal a Dutch ruling invalidating one of its patents covering Lipitor, the world's best-selling medicine with ales of $12.7 billion last year. Ranbaxy can appeal yesterday's ruling to Canada's Supreme Court. The order doesn't apply to litigation in other countries, including the U.S., Aristide said. ...more

Fentanyl pain patches recalled in Canada

From CTV News:
In the latest of several alerts on the safety of fentanyl pain-relief patches, Health Canada has announced the recall of two brands of the powerful patches.

The agency advises against using:

* 25 mcg/hr Duragesic (fentanyl transdermal system) patches sold by Janssen-Ortho Inc.
* 25 mcg/hr Ran Fentanyl Transdermal System patches sold by Ranbaxy.

Both products are being voluntarily recalled because they may have a cut along one side of the patch that could result in leaking of the fentanyl gel from the patch.

"Exposure to fentanyl gel that has leaked from the patch may lead to increased skin absorption and could result in serious, potentially life-threatening adverse events, including respiratory depression (slowed breathing) and possible overdose, which may be fatal," Health Canada said in its warning. ...more